Clinical Trials Logo

Cervical Intraepithelial Neoplasia clinical trials

View clinical trials related to Cervical Intraepithelial Neoplasia.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05613283 Active, not recruiting - Cervical Cancer Clinical Trials

Primary Cervical Cancer Screening by Self-sampling HPV Test

PREVENT
Start date: November 19, 2022
Phase:
Study type: Observational

Cervical cancer seriously threatens women's health and HPV infection is the main cause of cervical cancer. Traditionally, Cervical cancer screening is based on cervical exfoliated cell samples collected by health care provider, which is labor consuming and the coverage and compliance are both relatively low in some areas. Non-invasive hrHPV self-sampling test appears to be more acceptable and may improve the HPV screening coverage. This study aims to evaluate the clinical performance of a newly developed urine/vaginal self-sampling hrHPV test in Cervical cancer screening.

NCT ID: NCT05496231 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Start date: August 22, 2022
Phase: Phase 2
Study type: Interventional

The Main purpose of this study is to evaluate the safety and reactogenicity of GlaxoSmithKline Biologicals SA (GSK)'s investigational adjuvanted human papillomavirus (HPV) vaccine formulations.

NCT ID: NCT04859361 Active, not recruiting - Clinical trials for Intraepithelial Neoplasia, Cervical

Comparison of Treatment of Cervical Intraepithelial Lesions With Imiquimod or LLETZ

Start date: November 20, 2018
Phase: N/A
Study type: Interventional

Purpose: There are limited data on the success of conservative treatment of high-grade cervical squamous intraepithelial lesions (HSIL) with imiquimod directly compared to standard of treatment with LLETZ. LLETZ as standard treatment is possibly associated with premature labour, higher subfertility rate and a higher rate of spontaneous abortion. Since premature delivery is one of the most important causes of perinatal morbidity and mortality, alternative conservative methods for SIL treatment are constantly being evaluated. The immunomodulator imiquimod is one of the main target compounds for treating HSIL. Primary objective: to establish the efficacy of treatment with imiquimod (experimental arm) and compare it to the standard treatment with LLETZ (control arm). Secondary objective: - incidence and severity of the side effects in both groups; - need for treatment with LLETZ two years after primary treatment with imiquimod in the experimental arm or re-treatment with LLETZ two years after primary treatment with LLETZ in the control arm; - modulatory effect of imiquimod on immunoregulatory molecules. Study design: Single-centre randomized controlled intervention trial. Study population: 104 women with HSIL (52 in each arm). Intervention: - randomization in two arms: 1. Experimental arm (imiquimod): treatment for 16 weeks with 5% imiquimod. 2. Control arm (LLETZ). Successful treatment in the experimental arm is defined as absence of histological HSIL in diagnostic biopsies at 20-week follow-up (4 weeks after treatment completion) and in the control arm successful treatment is defined as absence of cytological HSIL in cytology 6 months after LLETZ (same as in our national guidelines).

NCT ID: NCT04704908 Active, not recruiting - Cervical Cancer Clinical Trials

Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)

Start date: February 6, 2021
Phase:
Study type: Observational

The primary objective of this study is to evaluate the immuno-persistence (type specific IgG antibody) of the tested vaccine administered in girls aged 9-17 years,comparing to young healthy adults of 18-26 years who received the standard 3-dose schedule (0,1,6 months).

NCT ID: NCT04537156 Active, not recruiting - Cervical Cancer Clinical Trials

Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)

Start date: September 5, 2020
Phase: Phase 3
Study type: Interventional

This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD., in healthy women aged 18-45 years old.

NCT ID: NCT04484415 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia Grade 2/3

Efficacy and Safety of Cevira® in Patients With Cervical Histologic High-grade Squamous Intraepithelial Lesions (HSIL)

APRICITY
Start date: November 10, 2020
Phase: Phase 3
Study type: Interventional

A double blind, prospective, randomized, placebo controlled, multi-center phase 3 study to evaluate efficacy and safety of Cevira® in patients with cervical histologic high-grade squamous intraepithelial lesions (HSIL).

NCT ID: NCT04073082 Active, not recruiting - Clinical trials for Hidradenitis Suppurativa

Safety and Efficacy of Laser Therapy in Gynaecology

Start date: July 24, 2019
Phase:
Study type: Observational

The aim of this study is to retrospectively evaluate the effectiveness and safety of Er:YAG laser for treatment of different gynecological indication, e.g. genital lesions, Bartholin's cyst, condyloma, episiotomy scars, lesions of hydradenitis suppurativa and use of laser in genital surgery used in private practice.

NCT ID: NCT03429582 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Comparison of Cervical CIN II/III Treatment Outcomes With Thermal Ablation Device

Start date: October 30, 2020
Phase: N/A
Study type: Interventional

The purpose of this academic-industrial partnership will be to compare two thermoablation modalities using devices adapted to low and middle income countries (LMICs) to traditional CO2-based cryotherapy for the treatment of cervical precancer. The investigators will investigate whether the cure rates of cervical intraepithelial neoplasia 2 and more severe diagnoses (CIN2+) with these devices are non-inferior compared to that of conventional cryotherapy. The results of this study will affect other research areas by serving as a springboard to exploring treatment alternatives that are amenable to low-resource settings and thus will reach the most vulnerable populations.

NCT ID: NCT03321461 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

TMTP1-ICG Mapping in Colposcopy-directed Biopsy

Start date: November 1, 2017
Phase: Phase 1
Study type: Interventional

Investigators aimed to determine the validity of the novel tumor targeted fluorescent TMTP1-ICG to increased accuracy of colposcopy-directed biopsy.

NCT ID: NCT03218436 Active, not recruiting - Clinical trials for Cervical Intraepithelial Neoplasia

Physical Cold Atmospheric Plasma for the Treatment of Cervical Intraepithelial Neoplasia

CAPCIN
Start date: August 31, 2017
Phase: N/A
Study type: Interventional

Cervical intraepithelial neoplasia will be treated with physical low temperature plasma in the plasma cohort compared to watchful waiting in the control cohort. Primary endpoint after 3-6 months: Pathological remission. Secondary endpoint: HPV remission.